| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
A clinician's perspective on a long time to publish
|
Peyrade, Frederic
|
|
2017
|
|
1 |
p. e11-
1 p.
|
artikel
|
| 2 |
A comprehensive view of pregnancy in patients with sickle cell disease in high-income countries: the need for robust data and further decline in morbidity and mortality
|
Joseph, Laure
|
|
|
|
1 |
p. e75-e84
|
artikel
|
| 3 |
Adolescents with Hodgkin lymphoma: a great treatment challenge
|
Mauz-Körholz, Christine
|
|
|
|
1 |
p. e5-e6
|
artikel
|
| 4 |
Alemtuzumab in T-cell large granular lymphocyte leukaemia
|
Kadia, Tapan M
|
|
2016
|
|
1 |
p. e4-e5
nvt p.
|
artikel
|
| 5 |
Alemtuzumab in T-cell large granular lymphocytic leukaemia: interim results from a single-arm, open-label, phase 2 study
|
Dumitriu, Bogdan
|
|
2016
|
|
1 |
p. e22-e29
nvt p.
|
artikel
|
| 6 |
A new player in IDH1 mutated myeloid neoplasias
|
Heuser, Michael
|
|
|
|
1 |
p. e7-e8
|
artikel
|
| 7 |
Apixaban versus no anticoagulation for the prevention of venous thromboembolism in children with newly diagnosed acute lymphoblastic leukaemia or lymphoma (PREVAPIX-ALL): a phase 3, open-label, randomised, controlled trial
|
O'Brien, Sarah H
|
|
|
|
1 |
p. e27-e37
|
artikel
|
| 8 |
A prognostic score for acute graft-versus-host disease based on biomarkers: a multicentre study
|
Levine, John E
|
|
2015
|
|
1 |
p. e21-e29
nvt p.
|
artikel
|
| 9 |
A resolution for health
|
The Lancet Haematology,
|
|
2016
|
|
1 |
p. e1-
1 p.
|
artikel
|
| 10 |
Are we ABL to do better for children with BCR–ABL1-like acute lymphocytic leukaemia?
|
Tasian, Sarah K
|
|
|
|
1 |
p. e6-e8
|
artikel
|
| 11 |
Artificial intelligence—refinement and possibilities
|
The Lancet Haematology,
|
|
|
|
1 |
p. e1
|
artikel
|
| 12 |
2020 ASH Annual Meeting
|
Cookson, Emma
|
|
|
|
1 |
p. e16-e17
|
artikel
|
| 13 |
2019 ASH Annual Meeting
|
Yaqub, Farhat
|
|
|
|
1 |
p. e12-e13
|
artikel
|
| 14 |
Assessing clonal haematopoiesis: clinical burdens and benefits of diagnosing myelodysplastic syndrome precursor states
|
Gondek, Lukasz P
|
|
|
|
1 |
p. e73-e81
|
artikel
|
| 15 |
Association between metformin use and progression of monoclonal gammopathy of undetermined significance to multiple myeloma in US veterans with diabetes mellitus: a population-based retrospective cohort study
|
Chang, Su-Hsin
|
|
2015
|
|
1 |
p. e30-e36
nvt p.
|
artikel
|
| 16 |
A statistician's perspective on a long time to publish
|
Dueck, Amylou C
|
|
2017
|
|
1 |
p. e12-
1 p.
|
artikel
|
| 17 |
A thank you to our peer reviewers of 2020
|
Smith, Lan-Lan
|
|
|
|
1 |
p. e10-e11
|
artikel
|
| 18 |
A world, connected
|
León, Andrés Gómez-De
|
|
|
|
1 |
p. e10
|
artikel
|
| 19 |
Barriers in the diagnosis of pulmonary embolism
|
Rezende, Suely Meireles
|
|
|
|
1 |
p. e11
|
artikel
|
| 20 |
Bendamustine–rituximab in mantle cell lymphoma
|
Lipsky, Andrew
|
|
2017
|
|
1 |
p. e2-e3
nvt p.
|
artikel
|
| 21 |
Biomarkers for GVHD prognosis
|
Betts, Brian
|
|
2015
|
|
1 |
p. e4-e5
nvt p.
|
artikel
|
| 22 |
Bishesh Poudyal: transplantation at a lifesaving discount
|
Cavanaugh, Ray
|
|
|
|
1 |
p. e19
|
artikel
|
| 23 |
Bortezomib, lenalidomide, and dexamethasone with or without elotuzumab in patients with untreated, high-risk multiple myeloma (SWOG-1211): primary analysis of a randomised, phase 2 trial
|
Usmani, Saad Z
|
|
|
|
1 |
p. e45-e54
|
artikel
|
| 24 |
Brentuximab vedotin plus nivolumab after autologous haematopoietic stem-cell transplantation for adult patients with high-risk classic Hodgkin lymphoma: a multicentre, phase 2 trial
|
Herrera, Alex F
|
|
|
|
1 |
p. e14-e23
|
artikel
|
| 25 |
Can paediatricians move directly to direct oral anticoagulants?
|
O'Brien, Sarah H
|
|
|
|
1 |
p. e2-e3
|
artikel
|
| 26 |
Can the treatment of myeloproliferative neoplasms be both good and bad for you?
|
Heaney, Mark L
|
|
|
|
1 |
p. e3-e4
|
artikel
|
| 27 |
Changing the paradigm of AML care in India
|
Singh, Amitabh
|
|
|
|
1 |
p. e9
|
artikel
|
| 28 |
Characterisation of rare haematological immune-related toxicities
|
Haanen, John B
|
|
2019
|
|
1 |
p. e10-e11
|
artikel
|
| 29 |
Chromosomal risk classification in high hyperdiploid acute lymphocytic leukaemia: the beginning of a new chapter
|
Borkhardt, Arndt
|
|
|
|
1 |
p. e9
|
artikel
|
| 30 |
Clinical course of light-chain smouldering multiple myeloma (idiopathic Bence Jones proteinuria): a retrospective cohort study
|
Kyle, Robert A
|
|
2014
|
|
1 |
p. e28-e36
nvt p.
|
artikel
|
| 31 |
Clinical trial reporting: an evolving process
|
The Lancet Haematology,
|
|
2017
|
|
1 |
p. e1-
1 p.
|
artikel
|
| 32 |
Closing in on targeted therapy for acute myeloid leukaemia
|
The Lancet Haematology,
|
|
2019
|
|
1 |
p. e1
|
artikel
|
| 33 |
Combination of ofatumumab and reduced-dose CHOP for diffuse large B-cell lymphomas in patients aged 80 years or older: an open-label, multicentre, single-arm, phase 2 trial from the LYSA group
|
Peyrade, Frédéric
|
|
2017
|
|
1 |
p. e46-e55
nvt p.
|
artikel
|
| 34 |
Concurrent treatment with two B-cell receptor pathway inhibitors
|
Robak, Tadeusz
|
|
2019
|
|
1 |
p. e8-e9
|
artikel
|
| 35 |
Consolidation anti-CD22 fractionated radioimmunotherapy with 90Y-epratuzumab tetraxetan following R-CHOP in elderly patients with diffuse large B-cell lymphoma: a prospective, single group, phase 2 trial
|
Kraeber-Bodere, Françoise
|
|
2017
|
|
1 |
p. e35-e45
nvt p.
|
artikel
|
| 36 |
Correction to Lancet Haematol 2023; 10: e46–58
|
|
|
|
|
1 |
p. e9
|
artikel
|
| 37 |
Correction to Lancet Haematol 2014; 1: e17–27
|
|
|
2014
|
|
1 |
p. e16-
1 p.
|
artikel
|
| 38 |
Correction to Lancet Haematol 2019; 6: e385–86
|
|
|
|
|
1 |
p. e11
|
artikel
|
| 39 |
Correction to Lancet Haematol 2019; 6: e398–408
|
|
|
|
|
1 |
p. e11
|
artikel
|
| 40 |
Correction to Lancet Haematol 2023; 10: e713–34
|
|
|
|
|
1 |
p. e10
|
artikel
|
| 41 |
Current status of phase 3 clinical trials in high-risk myelodysplastic syndromes: pitfalls and recommendations
|
Garcia-Manero, Guillermo
|
|
|
|
1 |
p. e71-e78
|
artikel
|
| 42 |
Dabigatran etexilate and treatment of acute venous thromboembolism in children
|
Kenet, Gili
|
|
|
|
1 |
p. e2-e3
|
artikel
|
| 43 |
Dabigatran etexilate for the treatment of acute venous thromboembolism in children (DIVERSITY): a randomised, controlled, open-label, phase 2b/3, non-inferiority trial
|
Halton, Jacqueline
|
|
|
|
1 |
p. e22-e33
|
artikel
|
| 44 |
10-day decitabine schedule in acute myeloid leukaemia: no extra bang for the buck
|
Cashen, Amanda F
|
|
2019
|
|
1 |
p. e6-e7
|
artikel
|
| 45 |
Diagnosis, grading, and treatment recommendations for children, adolescents, and young adults with sinusoidal obstructive syndrome: an international expert position statement
|
Mahadeo, Kris M
|
|
|
|
1 |
p. e61-e72
|
artikel
|
| 46 |
Diversity and Inclusion in Haematology
|
Marshall, Ariela
|
|
|
|
1 |
p. e14
|
artikel
|
| 47 |
Effectiveness and safety of apixaban versus rivaroxaban for prevention of recurrent venous thromboembolism and adverse bleeding events in patients with venous thromboembolism: a retrospective population-based cohort analysis
|
Dawwas, Ghadeer K
|
|
2019
|
|
1 |
p. e20-e28
|
artikel
|
| 48 |
Efficacy and safety of itacitinib versus placebo in combination with corticosteroids for initial treatment of acute graft-versus-host disease (GRAVITAS-301): a randomised, multicentre, double-blind, phase 3 trial
|
Zeiser, Robert
|
|
|
|
1 |
p. e14-e25
|
artikel
|
| 49 |
Eligibility criteria in haematological cancer clinical trials—what's needed?
|
Calissano, Mattia
|
|
|
|
1 |
p. e10
|
artikel
|
| 50 |
Eltrombopag for advanced myelodysplastic syndromes or acute myeloid leukaemia and severe thrombocytopenia (ASPIRE): a randomised, placebo-controlled, phase 2 trial
|
Mittelman, Moshe
|
|
2018
|
|
1 |
p. e34-e43
|
artikel
|
| 51 |
Eltrombopag reduces clinically relevant thrombocytopenic events in higher risk MDS and AML
|
Shastri, Aditi
|
|
2018
|
|
1 |
p. e6-e7
|
artikel
|
| 52 |
Epidemiological patterns of leukaemia in 184 countries: a population-based study
|
Miranda-Filho, Adalberto
|
|
2018
|
|
1 |
p. e14-e24
|
artikel
|
| 53 |
From clinical trials to real-world clinical practice: observations on the direct oral anticoagulants
|
Lip, Gregory Y H
|
|
2016
|
|
1 |
p. e2-e3
nvt p.
|
artikel
|
| 54 |
Gita Thanarajasingam: making treatment more tolerable
|
Davies, Rachael
|
|
|
|
1 |
p. e17
|
artikel
|
| 55 |
Graft-versus-host disease treatment beyond corticosteroids in newly diagnosed patients?
|
Paczesny, Sophie
|
|
|
|
1 |
p. e2-e3
|
artikel
|
| 56 |
GVHD risk assessment beyond current HLA evaluation
|
Paczesny, Sophie
|
|
|
|
1 |
p. e8-e9
|
artikel
|
| 57 |
Haematological immune-related adverse events induced by anti-PD-1 or anti-PD-L1 immunotherapy: a descriptive observational study
|
Delanoy, Nicolas
|
|
2019
|
|
1 |
p. e48-e57
|
artikel
|
| 58 |
Haematology: a critical field in health
|
The Lancet Haematology,
|
|
2014
|
|
1 |
p. e1-
1 p.
|
artikel
|
| 59 |
Heart failure and risk of venous thromboembolism: a systematic review and meta-analysis
|
Tang, Liang
|
|
2016
|
|
1 |
p. e30-e44
nvt p.
|
artikel
|
| 60 |
High-risk myeloma: a challenge to define and to determine the optimal treatment
|
Pawlyn, Charlotte
|
|
|
|
1 |
p. e4-e6
|
artikel
|
| 61 |
High-risk relapsed or refractory classic Hodgkin lymphoma cure: how to make the impossible possible
|
Gallamini, Andrea
|
|
|
|
1 |
p. e2-e3
|
artikel
|
| 62 |
How does zanubrutinib fare in treatment of B-cell malignancies?
|
Shirley, D'Sa
|
|
|
|
1 |
p. e5-e6
|
artikel
|
| 63 |
Hydroxyurea for primary stroke prevention in children with sickle cell anaemia in Nigeria (SPRING): a double-blind, multicentre, randomised, phase 3 trial
|
Abdullahi, Shehu U
|
|
|
|
1 |
p. e26-e37
|
artikel
|
| 64 |
Imaging bone-marrow activity with 18F-fluorothymidine PET
|
Shields, Anthony F
|
|
2018
|
|
1 |
p. e8-e9
|
artikel
|
| 65 |
Imaging of subclinical haemopoiesis after stem-cell transplantation in patients with haematological malignancies: a prospective pilot study
|
Williams, Kirsten M
|
|
2018
|
|
1 |
p. e44-e52
|
artikel
|
| 66 |
Indication and management of allogeneic haematopoietic stem-cell transplantation in myelofibrosis: updated recommendations by the EBMT/ELN International Working Group
|
Kröger, Nicolaus
|
|
|
|
1 |
p. e62-e74
|
artikel
|
| 67 |
Individualised versus standard duration of elastic compression therapy for prevention of post-thrombotic syndrome (IDEAL DVT): a multicentre, randomised, single-blind, allocation-concealed, non-inferiority trial
|
ten Cate-Hoek, Arina J
|
|
2018
|
|
1 |
p. e25-e33
|
artikel
|
| 68 |
Interferon in CML: back to the past, or towards the future?
|
Soverini, Simona
|
|
2015
|
|
1 |
p. e8-e9
nvt p.
|
artikel
|
| 69 |
Intravenous iron: out of sight, out of mind
|
Auerbach, Michael
|
|
2018
|
|
1 |
p. e10-e12
|
artikel
|
| 70 |
Is there a path forward for immunotherapy in patients with myelodysplastic syndromes?
|
Stahl, Maximilian
|
|
|
|
1 |
p. e5-e7
|
artikel
|
| 71 |
Lenalidomide maintenance after autologous haematopoietic stem-cell transplantation in mantle cell lymphoma: results of a Fondazione Italiana Linfomi (FIL) multicentre, randomised, phase 3 trial
|
Ladetto, Marco
|
|
|
|
1 |
p. e34-e44
|
artikel
|
| 72 |
Leukaemia prevalence worldwide: raising aetiology questions
|
Oliveira, Pedro Dantas
|
|
2018
|
|
1 |
p. e2-e3
|
artikel
|
| 73 |
Lucrèce Delicat-Loembet: offering hope to young people with sickle cell disease
|
Kirby, Tony
|
|
|
|
1 |
p. e11
|
artikel
|
| 74 |
Álvaro Urbano-Ispizua—a more accessible last chance for patients
|
Cavanaugh, Ray
|
|
|
|
1 |
p. e12
|
artikel
|
| 75 |
Management of drug–drug interactions of targeted therapies for haematological malignancies and triazole antifungal drugs
|
Brüggemann, Roger J
|
|
|
|
1 |
p. e58-e72
|
artikel
|
| 76 |
Managing the burden of sickle-cell disease in Africa
|
Piel, Frédéric B
|
|
2014
|
|
1 |
p. e11-e12
nvt p.
|
artikel
|
| 77 |
Mesenchymal stromal cells for steroid-refractory acute GVHD
|
Parody, Rocío
|
|
2016
|
|
1 |
p. e8-e9
nvt p.
|
artikel
|
| 78 |
Multiple keratoacanthomas in a patient with myelodysplastic syndrome
|
Zhu, Peiqiu
|
|
|
|
1 |
p. e94
|
artikel
|
| 79 |
Multiple myeloma: the puzzle is finally completed
|
Leleu, Xavier
|
|
2014
|
|
1 |
p. e4-e5
nvt p.
|
artikel
|
| 80 |
NICE guidance on caplacizumab for treating acute acquired thrombotic thrombocytopenia purpura
|
Hughes, Mary
|
|
|
|
1 |
p. e14-e15
|
artikel
|
| 81 |
Nilotinib and peginterferon alfa-2a for newly diagnosed chronic-phase chronic myeloid leukaemia (NiloPeg): a multicentre, non-randomised, open-label phase 2 study
|
Nicolini, Franck E
|
|
2015
|
|
1 |
p. e37-e46
nvt p.
|
artikel
|
| 82 |
Ofatumumab: another way to target CD20 in Waldenström's macroglobulinaemia?
|
Buske, Christian
|
|
2017
|
|
1 |
p. e4-e5
nvt p.
|
artikel
|
| 83 |
Olutasidenib alone or with azacitidine in IDH1-mutated acute myeloid leukaemia and myelodysplastic syndrome: phase 1 results of a phase 1/2 trial
|
Watts, Justin M
|
|
|
|
1 |
p. e46-e58
|
artikel
|
| 84 |
Once-weekly ofatumumab in untreated or relapsed Waldenström's macroglobulinaemia: an open-label, single-arm, phase 2 study
|
Furman, Richard R
|
|
2017
|
|
1 |
p. e24-e34
nvt p.
|
artikel
|
| 85 |
Oral decitabine–cedazuridine versus intravenous decitabine for myelodysplastic syndromes and chronic myelomonocytic leukaemia (ASCERTAIN): a registrational, randomised, crossover, pharmacokinetics, phase 3 study
|
Garcia-Manero, Guillermo
|
|
|
|
1 |
p. e15-e26
|
artikel
|
| 86 |
Oral decitabine plus cedazuridine versus intravenous decitabine
|
de Witte, Theo
|
|
|
|
1 |
p. e2-e3
|
artikel
|
| 87 |
Oral rivaroxaban versus enoxaparin with vitamin K antagonist for the treatment of symptomatic venous thromboembolism in patients with cancer (EINSTEIN-DVT and EINSTEIN-PE): a pooled subgroup analysis of two randomised controlled trials
|
Prins, Martin H
|
|
2014
|
|
1 |
p. e37-e46
nvt p.
|
artikel
|
| 88 |
Outcomes of paediatric patients with B-cell acute lymphocytic leukaemia with ABL-class fusion in the pre-tyrosine-kinase inhibitor era: a multicentre, retrospective, cohort study
|
den Boer, Monique L
|
|
|
|
1 |
p. e55-e66
|
artikel
|
| 89 |
PET-CT restaging: a surrogate for follicular lymphoma?
|
Cheson, Bruce D
|
|
2014
|
|
1 |
p. e2-e3
nvt p.
|
artikel
|
| 90 |
Ponatinib and blinatumomab for Philadelphia chromosome-positive acute lymphoblastic leukaemia: a US, single-centre, single-arm, phase 2 trial
|
Jabbour, Elias
|
|
|
|
1 |
p. e24-e34
|
artikel
|
| 91 |
Predicting cytopenias, progression, and survival in patients with clonal cytopenia of undetermined significance: a prospective cohort study
|
Cargo, Catherine
|
|
|
|
1 |
p. e51-e61
|
artikel
|
| 92 |
Predicting the progression of patients with CCUS to myeloid neoplasia
|
Groarke, Emma M
|
|
|
|
1 |
p. e7-e8
|
artikel
|
| 93 |
Prognostic value of PET-CT after first-line therapy in patients with follicular lymphoma: a pooled analysis of central scan review in three multicentre studies
|
Trotman, Judith
|
|
2014
|
|
1 |
p. e17-e27
nvt p.
|
artikel
|
| 94 |
Proliferation and differentiation
|
The Lancet Haematology,
|
|
|
|
1 |
p. e1
|
artikel
|
| 95 |
Radioimmunotherapy of lymphoma: an underestimated therapy option
|
Hohloch, Karin
|
|
2017
|
|
1 |
p. e6-e7
nvt p.
|
artikel
|
| 96 |
Rare and difficult to treat haematological diseases
|
The Lancet Haematology,
|
|
2015
|
|
1 |
p. e1-
1 p.
|
artikel
|
| 97 |
Refining pathological diagnoses in lymphoid malignancies
|
Lim, Soon Thye
|
|
2014
|
|
1 |
p. e13-e15
nvt p.
|
artikel
|
| 98 |
Risk of progression in MGUS
|
Rajkumar, S Vincent
|
|
2015
|
|
1 |
p. e6-e7
nvt p.
|
artikel
|
| 99 |
Risk of venous thromboembolism in patients with heart failure
|
Larsen, Torben Bjerregaard
|
|
2016
|
|
1 |
p. e6-e7
nvt p.
|
artikel
|
| 100 |
Rituximab, bendamustine, and low-dose cytarabine as induction therapy in elderly patients with mantle cell lymphoma: a multicentre, phase 2 trial from Fondazione Italiana Linfomi
|
Visco, Carlo
|
|
2017
|
|
1 |
p. e15-e23
nvt p.
|
artikel
|
| 101 |
Rivaroxaban compared with standard anticoagulants for the treatment of acute venous thromboembolism in children: a randomised, controlled, phase 3 trial
|
Male, Christoph
|
|
|
|
1 |
p. e18-e27
|
artikel
|
| 102 |
Role of HLA-B exon 1 in graft-versus-host disease after unrelated haemopoietic cell transplantation: a retrospective cohort study
|
Petersdorf, Effie W
|
|
|
|
1 |
p. e50-e60
|
artikel
|
| 103 |
Sabatolimab plus hypomethylating agents in previously untreated patients with higher-risk myelodysplastic syndromes (STIMULUS-MDS1): a randomised, double-blind, placebo-controlled, phase 2 trial
|
Zeidan, Amer M
|
|
|
|
1 |
p. e38-e50
|
artikel
|
| 104 |
Safety and activity of sintilimab in patients with relapsed or refractory classical Hodgkin lymphoma (ORIENT-1): a multicentre, single-arm, phase 2 trial
|
Shi, Yuankai
|
|
2019
|
|
1 |
p. e12-e19
|
artikel
|
| 105 |
Safety and effectiveness of oral rivaroxaban versus standard anticoagulation for the treatment of symptomatic deep-vein thrombosis (XALIA): an international, prospective, non-interventional study
|
Ageno, Walter
|
|
2016
|
|
1 |
p. e12-e21
nvt p.
|
artikel
|
| 106 |
Sequential azacitidine and lenalidomide in patients with high-risk myelodysplastic syndromes and acute myeloid leukaemia: a single-arm, phase 1/2 study
|
DiNardo, Courtney D
|
|
2015
|
|
1 |
p. e12-e20
nvt p.
|
artikel
|
| 107 |
Sex specific definitions of anaemia contribute to health inequity and sociomedical injustice
|
Weyand, Angela C
|
|
|
|
1 |
p. e6-e8
|
artikel
|
| 108 |
Should high-risk smouldering multiple myeloma be treated?
|
Richard, Shambavi
|
|
|
|
1 |
p. e15-e16
|
artikel
|
| 109 |
Should individuals who have been cured of hepatitis C virus and their partners be allowed to donate blood?
|
Aghemo, Alessio
|
|
|
|
1 |
p. e8-e10
|
artikel
|
| 110 |
Should patients with Ph-negative acute lymphoblastic leukaemia who reach minimal residual disease negativity have HSCT?
|
Boissel, Nicolas
|
|
|
|
1 |
p. e13-e14
|
artikel
|
| 111 |
Should patients with Ph-negative acute lymphoblastic leukaemia who reach minimal residual disease negativity have HSCT?
|
Chevallier, Patrice
|
|
|
|
1 |
p. e12-e13
|
artikel
|
| 112 |
Sintilimab: another effective immune checkpoint inhibitor in classical Hodgkin lymphoma
|
Ansell, Stephen M
|
|
2019
|
|
1 |
p. e2-e3
|
artikel
|
| 113 |
Splenomegaly in patients with primary or secondary myelofibrosis who are candidates for allogeneic hematopoietic cell transplantation: a Position Paper on behalf of the Chronic Malignancies Working Party of the EBMT
|
Polverelli, Nicola
|
|
|
|
1 |
p. e59-e70
|
artikel
|
| 114 |
Stockings to prevent post-thrombotic syndrome—where are we now?
|
Keeling, David
|
|
2018
|
|
1 |
p. e4-e5
|
artikel
|
| 115 |
Strengthening cancer care in Europe
|
The Lancet Haematology,
|
|
|
|
1 |
p. e1
|
artikel
|
| 116 |
Survival after mesenchymal stromal cell therapy in steroid-refractory acute graft-versus-host disease: systematic review and meta-analysis
|
Hashmi, Shahrukh
|
|
2016
|
|
1 |
p. e45-e52
nvt p.
|
artikel
|
| 117 |
Survival by age in paediatric and adolescent patients with Hodgkin lymphoma: a retrospective pooled analysis of children's oncology group trials
|
Kahn, Justine M
|
|
|
|
1 |
p. e49-e57
|
artikel
|
| 118 |
Symptom burden and quality of life in patients with high-risk essential thrombocythaemia and polycythaemia vera receiving hydroxyurea or pegylated interferon alfa-2a: a post-hoc analysis of the MPN-RC 111 and 112 trials
|
Mazza, Gina L
|
|
|
|
1 |
p. e38-e48
|
artikel
|
| 119 |
Targeted leukaemia therapy: a chemotherapy-free future?
|
The Lancet Haematology,
|
|
|
|
1 |
p. e1
|
artikel
|
| 120 |
58th American Society of Hematology Annual Meeting
|
Smith, Lan-Lan
|
|
2017
|
|
1 |
p. e13-e14
nvt p.
|
artikel
|
| 121 |
59th American Society of Hematology Annual Meeting
|
Yaqub, Farhat
|
|
2018
|
|
1 |
p. e13
|
artikel
|
| 122 |
56th American Society of Hematology Annual Meeting
|
Smith, Lan-Lan
|
|
2015
|
|
1 |
p. e10-e11
nvt p.
|
artikel
|
| 123 |
57th American Society of Hematology Annual Meeting
|
Smith, Lan-Lan
|
|
2016
|
|
1 |
p. e10-e11
nvt p.
|
artikel
|
| 124 |
The athlete biological passport: haematology in sports
|
Schumacher, Yorck Olaf
|
|
2014
|
|
1 |
p. e8-e10
nvt p.
|
artikel
|
| 125 |
The best direct-acting oral anticoagulant for treatment of venous thromboembolism?
|
Frere, Corinne
|
|
2019
|
|
1 |
p. e4-e5
|
artikel
|
| 126 |
The dawn of the CRISPR/Cas9 gene therapy era
|
The Lancet Haematology,
|
|
|
|
1 |
p. e1
|
artikel
|
| 127 |
The global burden of haematological diseases
|
The Lancet Haematology,
|
|
2018
|
|
1 |
p. e1
|
artikel
|
| 128 |
The M factor: maintenance in mantle cell lymphoma
|
Dreyling, Martin
|
|
|
|
1 |
p. e3-e4
|
artikel
|
| 129 |
The role of PET in first-line treatment of Hodgkin lymphoma
|
Trotman, Judith
|
|
|
|
1 |
p. e67-e79
|
artikel
|
| 130 |
The role of PET in the first-line treatment of the most common subtypes of non-Hodgkin lymphoma
|
Barrington, Sally F
|
|
|
|
1 |
p. e80-e93
|
artikel
|
| 131 |
The state of haematopoietic cells transplantation in Latin America
|
Jaimovich, Gregorio
|
|
|
|
1 |
p. e20-e21
|
artikel
|
| 132 |
The untold effect of the combined oral contraceptive pill on anticancer drugs
|
Mills, Georgia
|
|
|
|
1 |
p. e10-e11
|
artikel
|
| 133 |
Thromboprophylaxis in paediatric acute lymphoblastic leukaemia
|
Athale, Uma H
|
|
|
|
1 |
p. e3-e5
|
artikel
|
| 134 |
Time-to-death is a potential confounder in observational studies of blood transfusion in severe malaria
|
Watson, James A
|
|
|
|
1 |
p. e12
|
artikel
|
| 135 |
Time-to-death is a potential confounder in observational studies of blood transfusion in severe malaria – Authors' reply
|
Ackerman, Hans
|
|
|
|
1 |
p. e12-e13
|
artikel
|
| 136 |
Time to publish: challenging the performance of cooperative group lymphoma trials
|
Federico, Massimo
|
|
2017
|
|
1 |
p. e8-e10
nvt p.
|
artikel
|
| 137 |
Towards chemotherapy-free treatment of Philadelphia chromosome-positive acute lymphoblastic leukaemia
|
Boer, Judith M
|
|
|
|
1 |
p. e3-e5
|
artikel
|
| 138 |
Towards reparatory measures: blood donation, health systems, and men who have sex with men
|
Peace, Akadinma Eberechukwu
|
|
|
|
1 |
p. e13
|
artikel
|
| 139 |
Treating clots in cancer: moving closer to an answer?
|
Levine, Mark N
|
|
2014
|
|
1 |
p. e6-e7
nvt p.
|
artikel
|
| 140 |
Treating myelodysplastic syndromes: is more better?
|
Sekeres, Mikkael A
|
|
2015
|
|
1 |
p. e2-e3
nvt p.
|
artikel
|
| 141 |
Treatment with a 5-day versus a 10-day schedule of decitabine in older patients with newly diagnosed acute myeloid leukaemia: a randomised phase 2 trial
|
Short, Nicholas J
|
|
2019
|
|
1 |
p. e29-e37
|
artikel
|
| 142 |
Treosulfan-based or busulfan-based conditioning for allogeneic transplantation: the role of dose intensity
|
Shimoni, Avichai
|
|
|
|
1 |
p. e4-e5
|
artikel
|
| 143 |
Treosulfan or busulfan plus fludarabine as conditioning treatment before allogeneic haemopoietic stem cell transplantation for older patients with acute myeloid leukaemia or myelodysplastic syndrome (MC-FludT.14/L): a randomised, non-inferiority, phase 3 trial
|
Beelen, Dietrich Wilhelm
|
|
|
|
1 |
p. e28-e39
|
artikel
|
| 144 |
Ultrasound-accelerated catheter-directed thrombolysis versus anticoagulation for the prevention of post-thrombotic syndrome (CAVA): a single-blind, multicentre, randomised trial
|
Notten, Pascale
|
|
|
|
1 |
p. e40-e49
|
artikel
|
| 145 |
Umbralisib in combination with ibrutinib in patients with relapsed or refractory chronic lymphocytic leukaemia or mantle cell lymphoma: a multicentre phase 1–1b study
|
Davids, Matthew S
|
|
2019
|
|
1 |
p. e38-e47
|
artikel
|
| 146 |
Using it wisely: catheter-directed thrombolysis for deep vein thrombosis
|
Vedantham, Suresh
|
|
|
|
1 |
p. e6-e7
|
artikel
|
| 147 |
Using Twitter for the identification of COVID-19 vaccine-associated haematological adverse events
|
Bennett, Charles L
|
|
|
|
1 |
p. e12-e13
|
artikel
|
| 148 |
Vaccine-induced immune thrombotic thrombocytopenia
|
Klok, Frederikus A
|
|
|
|
1 |
p. e73-e80
|
artikel
|
| 149 |
Women with haemophilia also exist
|
Pascual, Ana
|
|
|
|
1 |
p. e18
|
artikel
|
| 150 |
Zanubrutinib in patients with previously treated B-cell malignancies intolerant of previous Bruton tyrosine kinase inhibitors in the USA: a phase 2, open-label, single-arm study
|
Shadman, Mazyar
|
|
|
|
1 |
p. e35-e45
|
artikel
|
Tijdschrift beschrijving